Nov 8, 2011
SANTA MONICA, Calif., Nov. 8, 2011 /PRNewswire/ -- Reprints Desk, Inc., a Derycz Scientific (OTC.BB: DYSC) company, today announced that Reprints Desk's Global Sales Director Armand Brevig will present key research findings from an independently commissioned research study on bibliographic management practices and scientific literature usage at the 2011 Pharma-Bio-Med & BioSciences Conference in Venice, Italy. The presentation titled "Bibliographic Management Practices & Scientific Literature Usage" will be held Tuesday, 15 November at 9:40 a.m.
Ian Palmer, Head of Marketing at Reprints Desk, said, "Scientific journal articles are critical tools for Life Science professionals across research, information management, product marketing, regulatory and medical affairs. We're eager to share our analysis and revelatory findings in regards to researcher processes and preferences, journal article consumption drivers and data, information management professionals' role in managing and supporting literature acquisition processes, current awareness service considerations, and marketing and compliance considerations."
The annual Pharma-Bio-Med & BioSciences event, produced by InfoGlobal, is tailored for life sciences professionals and information managers. This year's conference topics will include translational medicine in research, drug pipeline data, STM and sequence searching, information from mobile devices, data management and competitive insights from clinical trials databases, global copyright compliance, scientific literature workflows, text mining, library marketing, drug information awareness, global coordination of medical information services, and more.
For more information about the Pharma-Bio-Med Conference and Exposition, visit the event website online at http://www.pharma-bio-med.com. For more information about Reprints Desk, visit www.reprintsdesk.com.
About Reprints Desk®
Reprints Desk improves how journal articles and clinical reprints are accessed, procured, and legally used in evidence-based promotions and scientific, technical, and medical (STM) research. Organizations based on intellectual property (IP) choose Reprints Desk because of its collaborative business approach, efficient article supply system and services, and commitment to quality post-sales support. Outsell Inc., an independent analyst and advisory firm, ranked Reprints Desk #1 in the most recent Document Delivery Vendor Scorecard.
About Derycz Scientific®
Derycz Scientific, Inc. develops companies, products, services and systems that facilitate the re-use of published content in a manner that helps organizations achieve their marketing, communication and research goals effectively and in compliance with copyright law and regulatory rules. Its subsidiary companies include Reprints Desk, Inc., Pools Press, Inc. and Techniques Appliquees aux Arts Graphiques, S.p.A. (TAAG). For more information, please visit www.deryczscientific.com.
Certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in obtaining new customers; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; the Company's success in integrating acquired entities and assets, and all the risks and related information described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"), including the financial statements and related information contained in the Company's Annual Report on Form 10-K. The Company assumes no obligation to update the cautionary information in this release.
Public and Media Relations Contacts:
Ian Palmer, Head of Marketing
Reprints Desk, Inc. | +1 (415) 533.8308
SOURCE Reprints Desk, Inc.